Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: Use of a dose-response model

Fundamental and Clinical Pharmacology

Volumn 29, Issue 2, 2015, Pages 209-218

  Bays, Harold E ^a   Chen, Erluo ^b   Tomassini, Joanne E ^b   Mcpeters, Gail ^b   Polis, Adam B ^b   Triscari, Joseph ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; Clinical equivalence; Ezetimibe; LDL C lowering; Modeling and simulation

Indexed keywords

ATORVASTATIN; ATORVASTATIN PLUS EZETIMIBE; EZETIMIBE; LIPID; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; DRUG COMBINATION; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALLERGIC REACTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED;

AGED; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED;

EID: 84924767119     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12096     Document Type: Article

References (38)

1. Bays H.E., Neff D., Tomassini J.E., Tershakovec A.M. Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. (2008) 6 447-470.
2. Catapano A.L., Toth P.P., Tomassini J.E., Tershakovec A.M. The efficacy and safety of ezetimibe co-administered with statin therapy in various patient groups. Clin. Lipidol. (2013) 8 13-41.
3. Merck & Co., Inc. [product insert]. Vytorin (ezetimibe/simvastatin). Merck & Co., Inc., Whitehouse Station, NJ, 2014.
4. Toth P.P., Catapano A., Tomassini J.E., Tershakovec A.M. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin. Lipidol. (2010) 5 655-684.
5. Abd T.T., Jacobson T.A. Statin-induced myopathy: a review and update. Expert Opin. Drug Saf. (2011) 10 373-387.
6. Davidson M.H., Robinson J.G. Safety of aggressive lipid management. J. Am. Coll. Cardiol. (2007) 49 1753-1762.
7. Pasternak R.C., Smith S.C. Jr, Bairey-Merz C.N. et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation (2002) 106 1024-1028.
8. US Food and Drug Administration: FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. US FDA, http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm, 2012.
9. Pfizer: [package insert]. Lipitor (atorvastatin calcium) tablets. Pfizer, New York, NY, 2014.
10. Bays H.E., Averna M., Majul C. et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am. J. Cardiol. (2013) 112 1885-1895.
11. Conard S.E., Bays H.E., Leiter L.A. et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am. J. Cardiol. (2008) 102 1489-1494.
12. Cruz-Fernandez J.M., Bedarida G.V., Adgey J. et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int. J. Clin. Pract. (2005) 59 619-627.
13. Leiter L.A., Bays H., Conard S. et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am. J. Cardiol. (2008) 102 1495-1501.
14. Zieve F., Wenger N.K., Ben Yehuda O. et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am. J. Cardiol. (2010) 105 656-663.
15. Merck & Co., Inc. [package insert] Liptruzet (ezetimibe/atorvastatin). Merck & Co., Inc., Whitehouse Station, NJ, 2013.
16. ™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol. http://www.mercknewsroom.com/press-release/research-and-development-news/fda-approves-mercks-liptruzet-ezetimibe-and-atorvastatin. 2014.
17. Vargo R., Adewale A., Behm M.O., Mandema J., Kerbusch T. Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses. Clin. Pharmacol. Ther. (2014) 96 101-109.
18. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika (1947) 12 153-157.
19. Kauffman A.B., Olson K.L., Youngblood M.L. et al. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease. J. Clin. Lipidol. (2010) 4 173-180.
20. Kitkungvan D., Lynn Fillipon N.M., Dani S.S., Downey B.C. Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease. J. Clin. Lipidol. (2010) 4 293-297.
21. Waters D.D., Brotons C., Chiang C.W. et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation (2009) 120 28-34.
22. Kesaniemi A. Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials. Fundam. Clin. Pharmacol. (2007) 21(Suppl) 29-30.
23. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol. (2010) 24 19-28.
24. Baigent C., Landray M.J., Reith C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (2011) 377 2181-2192.
25. Holme I., Boman K., Brudi P. et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am. J. Cardiol. (2010) 105 1802-1808.
26. Rossebo A.B., Pedersen T.R., Boman K. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. (2008) 359 1343-1356.
27. Cannon C.P., On behalf of the IMPROVE-IT investigators. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial. Presented at the American Heart Association Scientific Sessions 2014. http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469669.pdf
28. Ballantyne C.M., Houri J., Notarbartolo A. et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation (2003) 107 2409-2415.
29. Merck & Co., Inc. [product insert] Zetia. Merck & Co., Inc., Whitehouse Station, NJ, 2014.
30. Ballantyne C.M., Lipka L.J., Sager P.T. et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int. J. Clin. Pract. (2004) 58 653-658.
31. Kastelein J.J., Akdim F., Stroes E.S. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. (2008) 358 1431-1443.
32. Peto R., Emberson J., Landray M. et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. (2008) 359 1357-1366.
33. Castellano J.M., Sanz G., Peñalvo J.L. et al. A polypill strategy to improve adherence: results from the FOCUS project. J. Am. Coll. Cardiol. (2014). pii: S0735-1097(14)05941-5
34. Chapman R.H., Pelletier E.M., Smith P.J., Roberts C.S. Can adherence to antihypertensive therapy be used to promote adherence to statin therapy? Patient Prefer. Adherence (2009) 3 265-275.
35. Chapman R.H., Yeaw J., Roberts C.S. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc. Disord. (2010) 10 29.
36. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension (2010) 55 399-407.
37. Hussein M.A., Chapman R.H., Benner J.S. et al. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study. Am. J. Cardiovasc. Drugs (2010) 10 193-202.
38. Thom S., Poulter N., Field J. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 310 918-929.